Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review

Authors

Silv Fu (ORCID: https://orcid.org/0000-0002-0069-0115)
Chunguo Pan
Zhihua Liu (ORCID: https://orcid.org/0000-0003-4242-033X)
Lei Wang (ORCID: https://orcid.org/0000-0002-3625-506X)
Yue Zhuang
Qiang Wen (ORCID: https://orcid.org/0000-0002-2923-8851)

Institutions

Jiangxi Provincial Cancer Hospital (CN)

Publication Details

Journal: Frontiers in Pharmacology
Published: 2025-12-19
DOI: https://doi.org/10.3389/fphar.2025.1707050
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review

Silv Fu, Chunguo Pan, Zhihua Liu, Lei Wang et al.

Dec 19, 2025

Frontiers in Pharmacology

Lung Cancer Treatments and Mutations

article

Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review

Silv Fu, Chunguo Pan, Zhihua Liu, Lei Wang, Yue Zhuang, Qiang Wen

December 19, 2025article en

Abstract

No abstract available for this paper.

Frontiers in PharmacologyVol. 16

Jiangxi Provincial Cancer Hospital (CN)

Openalex Percentile: Top 40%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review — Silv Fu, Chunguo Pan, et al. · Frontiers in Pharmacology (2025) | TGRS Research Map | TGRS